Stanton L. Gerson, MD, director of the Case Comprehensive Cancer Center, in Cleveland, is the new president of the Association of American Cancer Institutes (AACI). His presidential initiative aims to improve patient outcomes and health care value in the community.
Researchers at The University of Texas MD Anderson Cancer Center have developed a new personalized assessment tool that could better predict lung cancer risk in never, light and heavy smokers using a large Taiwanese prospective cohort study.
As published in JNCCN, a recent project out of Canada shows that programs identifying stress and distress in patients with cancer increase health care professionals’ confidence and awareness of patient-centeredness; outcomes are influenced by site-based navigators and practice size.
Fred Hutchinson Cancer Research Center today announced the official opening of a first-of-its-kind clinic dedicated to providing innovative immunotherapies for cancer patients in clinical trials.
When it comes to prostate cancer biopsies, risk and reality don’t always match up, according to research published online today in the Journal of Clinical Oncology. Investigators from SWOG, the cancer clinical trials network funded by the National Cancer Institute (NCI), found widespread detection bias after a fresh examination of data from the two largest prostate cancer prevention trials ever conducted in the United States.
University of Colorado Cancer Center study published in the journal Gynecologic Oncology shows that only 44 percent of patients in a large, national sample received all three components of standard-of-care treatment, most often lacking brachytherapy.
Jennifer Klemp, PhD, MPH, director of cancer survivorship and an associate professor at The University of Kansas Cancer Center, is interviewed by Oncology Nursing News. In this interview, Klemp offers insights on some of the critical issues that clinicians face, among them: how to deliver optimal survivorship care, what ingredients go into the plan, how to measure progress, and how is this care reimbursed.
The FDA granted approval to pembrolizumab for the first-line treatment of patients with metastatic non–small cell lung cancer whose tumors express programmed death ligand-1 as determined by an FDA–approved test.
The recent approval of pembrolizumab (Keytruda) in recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) following progression on a platinum-based chemotherapy was a significant advancement for the disease. However, Barbara A. Burtness, MD, said, the approval of the PD-1 inhibitor only scratches the surface of the potential of immunotherapies in head and neck cancer.
Acute myeloid leukemia (AML) is an aggressive cancer known for drug resistance and relapse. In an effort to uncover new treatment strategies, researchers at University of California San Diego School of Medicine and Moores Cancer Center discovered that a cell surface molecule known as CD98 promotes AML. The study also shows that inhibiting CD98 with the therapeutic antibody IGN523 blocks AML growth in patient-derived cells and mouse models.
University of Colorado Cancer Center study shows that comparing cancer cell sequencing results to published reference genomes may be less accurate than comparing to healthy cell from same organism.
The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science (IACS) has initiated the first clinical study of a novel drug designed to starve cancer cells, IACS-10759.
Spurred by NYS Trade Mission to Cuba in 2015, Buffalo cancer center will conduct a clinical trial with CIMAvax-EGF, groundbreaking immunotherapy for lung cancer developed in Cuba — becoming the first American center to receive FDA authorization to sponsor a clinical trial offering a Cuban-made therapy to U.S. patients — and will work to speed this and other innovative therapies to patients worldwide through a historic new business venture with Cuban research institute
A Rutgers Cancer Institute of New Jersey researcher has received a $596,250 award (W81XWH-16-1-0358) from the U.S. Department of Defense to study the role of chronic stress in breast cancer development. The focus of the work is to explore how chronic stress impacts breast cancer risk and to provide a foundation that can guide prevention strategies.
Patients with disseminated advanced cancer who undergo surgery are far more likely to endure long hospital stays and readmissions, referrals to extended care facilities and death, UC Davis researchers have found.
Painful sex in women after cancer treatment is relatively common, often treatable and needs to be addressed by medical providers, a UC Davis oncologist and researcher suggests.
A team of researchers led by UC San Francisco scientists has identified a new drug target for triple-negative breast cancer, an aggressive disease subtype that has the poorest outcomes and accounts for as many as one in five cases. The findings are particularly noteworthy because drugs that act on the newly discovered target, a protein known as PIM1, are already in clinical trials for leukemia and multiple myeloma.
Tonya Edwards, a clinical nurse in Palliative Care at The University of Texas MD Anderson Cancer Center, is the recipient of the 2016 Brown Foundation Award for Excellence in Oncology Nursing.
José R. Conejo-Garcia, M.D., Ph.D. has joined Moffitt Cancer Center as co-leader of the Immunology Program and chair of the Department of Immunology.
A Ludwig Cancer Research study published in the current issue of Scientific Reports describes a new method and risk model to assess how aggressive a bladder cancer is likely to be. “If confirmed in larger studies, our findings could help physicians get a better handle on how a patient’s bladder cancer is likely to progress and allow them to personalize treatment on the basis of that knowledge,” said Ralph Weichselbaum, director of the Ludwig Center at Chicago University, who led the study.
Understanding how multiple myeloma develops and responds to therapies may be easier using a new mouse model developed at Yale University School of Medicine. The model supports the growth of cells derived from patients with multiple myeloma or the disease’s precursor states.
Researchers at the Yale School of Medicine have identified a chemical inhibitor that limits the growth of lung tumor cells. The inhibitor works by partially disrupting glycosylation, the addition of sugar chains to proteins.
In a recent study, senior author and Yale pathology professor Wang Min demonstrated that the tumors release substances called cytokines to attract macrophages.
Cancer Moonshot Task Force Executive Director Greg Simon will speak at the 2016 AACI/CCAF Annual Meeting on Tuesday, October 25, in Chicago.
Searching for more individual genes to predict responses to breast cancer therapy may not work, a new study suggests. Instead, scientists and clinicians need to pay attention to abnormalities in networks of genes, Yale researchers report in a paper published Oct. 20 in the journal Annals of Oncology.
Fred Hutchinson Cancer Research Center today announced the appointment of Dr. Bruce Clurman to serve as its executive vice president and deputy director, effective Nov. 1.
When Memorial Sloan Kettering opened its doors along Commack Road in 2002, eastern Long Islanders no longer needed to navigate congested roadways and train lines bound for Manhattan to receive personalized cancer care. Today, more than 14 years later, MSK is reinforcing its commitment to the local community in the form of a 38,000-plus-square-foot addition complete with enhancements to both clinical programs and physical spaces.
The 2016 joint annual meeting of the Association of American Cancer Institutes (AACI) and the Cancer Center Administrators Forum (CCAF), October 23-25, in Chicago, will feature three panel discussions focused on precision medicine, and an update on AACI’s Academic Difference Initiative.
Worsening depression symptoms are associated with shorter survival for lung cancer patients, particularly those in the early stages of disease, according to a new U.S. study.
A Ludwig Cancer Research study has identified a metabolic vulnerability in the aggressive and incurable brain cancer glioblastoma (GBM) and shown how it can potentially be exploited for therapy.
Currently, human papillomavirus (HPV) vaccination rates remain low across the U.S., with fewer than 40% of girls and just over 21% of boys receiving the recommended vaccine series. Research from Roswell Park Cancer Institute has identified barriers that need to be overcome to improve vaccination rates, as well as possible strategies for doing so. The study has been published online ahead of print in the Journal of Cancer Education.
Researchers in the multidisciplinary PanCuRx research initiative at the Ontario Institute for Cancer Research (OICR) and University Health Network’s Princess Margaret Cancer Centre, led by Dr. Faiyaz Notta and Dr. Steven Gallinger, today published new findings that challenge current beliefs about how and why pancreatic cancer is so aggressive.
To develop new approaches to cancer prevention, scientists have attempted to grow tumor cells from precursor states in animal models.
The University of Texas MD Anderson Cancer Center and the Houston Independent School District (HISD) have reached a first-of-its-kind agreement to provide access to an evidence-based, youth-oriented tobacco prevention and cessation program for all 110,000 HISD middle and high school students.
In a major breakthrough for ovarian and uterine cancers, Yale researchers have defined the genetic landscape of rare, highly aggressive tumors called carcinosarcomas (CSs), pointing the way to possible new treatments.
Fred Hutchinson Cancer Research Center today announced that Dr. Nancy E. Davidson, director of the University of Pittsburgh Cancer Institute, has accepted the position of executive director of clinical oncology for the Fred Hutch / University of Washington Cancer Consortium, one of 47 National Cancer Institute-designated Comprehensive Cancer Centers nationwide. Her appointment will become effective Dec. 1.
In a phase I clinical trial, patients with previously treated advanced non-small cell lung cancer (NSCLC) have showed initial response and disease control from the drug combination of ramucirumab and pembrolizumab. Roy S. Herbst, MD, PhD, Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital at Yale New Haven, will present the interim data of the clinical trial at the European Society for Medical Oncology (ESMO) Congress today.
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, ribociclib, in combination with the aromatase inhibitor letrozole, dramatically improved progression-free survival (PFS) of post-menopausal women with hormone receptor-positive metastatic breast cancer, compared to the hormone therapy alone.
African-American and Hispanic men in the United States are less likely to receive therapy for prostate cancer compared to Caucasian men — even when they have more aggressive disease, according to new research from Roswell Park Cancer Institute and Vanderbilt University Medical Center. The study, senior authored by Willie Underwood, III, MD, MPH, MSci, of Roswell Park, has been published online ahead of print in the journal Urology.
Clarivate Analytics announced its third place win with Georgetown University in the USPTO Cancer Moonshot Challenge held by the U.S. Commerce Department’s United States Patent and Trademark Office.
After an extensive national search, Smilow Cancer Hospital and Yale Cancer Center (YCC) have announced that Charles S. Fuchs, MD, MPH, will become the new YCC director and physician-in-chief at Smilow Cancer Hospital, effective Jan. 1, 2017.
The European Bioinformatics Institute (EMBL-EBI), the New York University School of Medicine and the Ontario Institute for Cancer Research (OICR) today announced a major milestone in the Reactome project: the annotation and release of its 10,000th human protein, making it the most comprehensive open access pathway knowledgebase available to the scientific community.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right